
Boston Scientific company profile
$44.34+0.32%Close 13 Nov 2026 · Market value $63.59B
About Boston Scientific
Boston Scientific develops and manufactures medical devices and therapies that help physicians diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Its core businesses are organized into two reportable segments, MedSurg and Cardiovascular, spanning business units including Endoscopy, Urology, Neuromodulation, Interventional Cardiology and Vascular Therapies, Electrophysiology, Cardiac Rhythm Management, and Interventional Oncology and Embolization. Key products include the WATCHMAN left atrial appendage closure devices, the FARAPULSE pulsed field ablation system and the SpyGlass single-use scopes. The company sells to hospitals, clinics, outpatient facilities and medical offices in 127 countries, largely through direct sales organizations and supplemented by distributors and dealers.
A summary of the business section of the company's latest annual report, filed 17 Feb 2026.
Company facts
| Ticker | BSX · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 885725 |
|---|
| Latest annual report | 10-K, filed 17 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Michael F. Mahoney | Chairman, President & CEO · Director | 3.3M · < 1% | Open-market purchase, 3 Aug 2026 |
|---|
| Joseph M. Fitzgerald | EVP & Group Pres, Cardiology | 670K · < 1% | Code I, 31 Jul 2026 |
|---|
| Daniel J. Brennan | EVP and CFO | 555K · < 1% | Option exercise, 19 Feb 2025 |
|---|
| Jeffrey B. Mirviss | EVP&Pres, Periph Intervent | 365K · < 1% | Sale under a 10b5-1 plan, 25 Feb 2025 |
|---|
| Arthur C. Butcher | EVP& Grp Pres, MedSurg & APAC | 268K · < 1% | Shares withheld for tax, 2 May 2026 |
|---|
| Jonathan R. Monson | EVP and CFO | 141K · < 1% | Code I, 10 Aug 2026 |
|---|
| Vance R. Brown | EVP, GC and Corp. Secretary | 137K · < 1% | Shares withheld for tax, 16 Feb 2026 |
|---|
| John E. Sununu | Director | 136K · < 1% | Grant or award, 8 May 2025 |
|---|
| Edward J. Ludwig | Director | 62.3K · < 1% | Open-market purchase, 31 Jul 2026 |
|---|
| David S. Wichmann | Director | 48.0K · < 1% | Grant or award, 7 May 2026 |
|---|
| Yoshiaki Fujimori | Director | 38.8K · < 1% | Open-market sale, 29 Jul 2025 |
|---|
| Ellen M. Zane | Director | 24.1K · < 1% | Grant or award, 7 May 2026 |
|---|
| Susan E. Morano | Director | 10.6K · < 1% | Open-market purchase, 25 Aug 2026 |
|---|
| Jessica L. Mega | Director | 8.2K · < 1% | Grant or award, 7 May 2026 |
|---|
| Cheryl Pegus | Director | 5.9K · < 1% | Open-market purchase, 20 May 2026 |
|---|
| David C. Habiger | Director | 5.6K · < 1% | Open-market purchase, 5 Aug 2026 |
|---|
| Christophe P. Weber | Director | 879 · < 1% | Grant or award, 7 May 2026 |
|---|
| O'Connor Padraig Andrew | EVP, Global Operations | — | Option exercise, 2 Sep 2026 |
|---|
| Woodworth Emily | SVP, Global Controller and CAO | — | Code I, 11 Aug 2026 |
|---|
| O'Sullivan Miriam | SVP, Chief HR Officer | — | Shares withheld for tax, 16 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
BSX in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.